Titre
Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Delforge, M.
Auteure/Auteur
Minuk, L.
Auteure/Auteur
Eisenmann, J.C.
Auteure/Auteur
Arnulf, B.
Auteure/Auteur
Canepa, L.
Auteure/Auteur
Fragasso, A.
Auteure/Auteur
Leyvraz, S.
Auteure/Auteur
Langer, C.
Auteure/Auteur
Ezaydi, Y.
Auteure/Auteur
Vogl, D.T.
Auteure/Auteur
Giraldo-Castellano, P.
Auteure/Auteur
Yoon, S.S.
Auteure/Auteur
Zarnitsky, C.
Auteure/Auteur
Escoffre-Barbe, M.
Auteure/Auteur
Lemieux, B.
Auteure/Auteur
Song, K.
Auteure/Auteur
Bahlis, N.J.
Auteure/Auteur
Guo, S.
Auteure/Auteur
Monzini, M.S.
Auteure/Auteur
Ervin-Haynes, A.
Auteure/Auteur
Houck, V.
Auteure/Auteur
Facon, T.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1592-8721
Statut éditorial
Publié
Date de publication
2015
Volume
100
Numéro
6
Première page
826
Dernière page/numéro d’article
833
Peer-reviewed
Oui
Langue
anglais
Résumé
We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexamethasone, and melphalan, prednisone, thalidomide improved patients' health-related quality-of-life from baseline over the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalidomide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeated-measures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and low-dose dexamethasone delays disease progression versus melphalan, prednisone, thalidomide and has been associated with a clinically meaningful improvement in health-related quality-of-life. These results further establish continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone, thalidomide.
PID Serval
serval:BIB_88BF6238C995
PMID
Open Access
Oui
Date de création
2015-08-27T08:53:36.882Z
Date de création dans IRIS
2025-05-21T00:38:04Z